Acute lung damage is one of the most common types of serious sickness, and despite its high death rate and rapid progression, there is presently no clinically effective treatment for it. The significance of gene therapy in acute lung injury has grown over time as our understanding of the disease's pathological mechanism has deepened. Gene therapy for acute lung injury now focuses mostly on improving alveolar fluid clearance, reducing pro-inflammatory response, and mending lung barrier. Viral and non-viral vectors are currently used as gene delivery vehicles. Though less efficient than viral vectors, non-viral delivery technologies have the advantages of being less immunogenic, more affordable, and easier to mass-produce.
